2024-05-24
Share：
From May 16 to 19, the China Hospital Information Network Conference (CHIMA 2024) was grandly held at the Nanjing International Exhibition Center. The conference saw participation from renowned experts and scholars in the field of medical health informatization from both the National Health Commission and internationally, who engaged in in-depth discussions on the theme of "Deepening Application, Integrated Innovation, and Information Technology Empowering High-Quality Hospital Development." On the afternoon of May 18, Huawei hosted a themed summit titled "Digital Intelligence Driven, Building a Healthy China Innovation Foundation," where, in the presence of many experts from the medical field, DHC Technology Co., Ltd. (hereinafter referred to as "DHC") and Huawei Technologies Co., Ltd. (hereinafter referred to as "Huawei") held an AI medical research cooperation signing ceremony at the summit.
Huawei, a global leader in ICT (Information and Communications Technology) infrastructure and smart devices, possesses top-notch ICT technology strength and high-performance computing and storage capabilities. DHC, recognized as a "world-class, domestically leading" enterprise in medical big data and artificial intelligence, boasts strong technical advantages and extensive practical experience in the medical field. This milestone cooperation will reshape the development process of domestic medical digitalization, comprehensively promote the transformation and upgrading of the healthcare industry, and have a profound impact on accelerating the high-level development of public hospitals and building an intelligent medical ecosystem.
The signing ceremony was attended by leaders from both companies: Lu Yongping (left two), Director of Huawei's China Government, Education, and Healthcare Systems Department; Shi Wenzhao (right), Chairman and CEO of DHC; Guo Zhongguang (left three), General Manager of Huawei's Healthcare Industry in the Education and Healthcare Systems Department; Li Xia (right three), General Manager of DHC's Sales Center; Zhang Lihua (left one), General Manager of Huawei's China Government, Education, and Healthcare Systems Department's Partner Development and Management Department; and Wang Kefeng (right one), Senior Director of DHC's Solutions Department.
Together, they aim to promote high-quality development in the medical industry.
For teaching hospitals and regional medical centers, leveraging DHC's strong data services and clinical research capabilities in the smart medical field, combined with Huawei's Ascend AI computing power, both parties will collaborate to create an integrated multimodal big data solution. This aims to address issues such as large volumes of clinical data, heterogeneity across systems, and difficulties in integration. They will build an efficient hospital-level multimodal big data center foundation, offering full-chain, one-stop intelligent data processing capabilities for clinical data such as medical records, imaging, pathology, and omics. This will provide intelligent applications like clinical assistance in diagnosis, scientific research analysis, and operational decision-making, fully empowering each link of "medical-educational-research-management" and helping hospitals achieve a competitive edge in high-quality development.
For disease-specific medical centers and experts, utilizing DHC's international general data models, terminology systems (such as SNOMED CT), and core technologies like federated learning, in conjunction with Huawei Cloud HCS foundation and products like Data Lake MRS, a multicenter, multimodal distributed big data research joint solution will be developed. This establishes a unified distributed data service platform that integrates main and branch centers, helping domain experts set up cross-institutional, multicenter, distributed dynamic continuously updated data centers while ensuring data security. This facilitates rapid large-scale cohort studies, specialized disease management and quality control, effectively improving the homogeneity level of disease diagnosis and treatment, enhancing multicenter research collaboration efficiency and level, and accelerating the production and application transformation of high-quality research outcomes.
For clinical departments, based on DHC's multimodal clinical decision support technology, proprietary vertical domain big models in healthcare, and authoritative medical knowledge bases, combined with Huawei's foundational innovative products, a specialized multimodal clinical decision support joint solution will be created. This establishes departmental specialized disease databases, offering intelligent decision support services through multimodal data fusion algorithms, providing professional intelligent Q&A, literature summaries, discharge summaries, and other intelligent services based on big models. This allows intelligent technology to fully empower departments, thereby improving doctors' work efficiency, diagnostic accuracy, quality of care, reducing medical costs, enhancing patient satisfaction, and overall improving the departmental level of medical services.
With complementary advantages, they lead the comprehensive digital transformation in the medical field.
In the wave of global digital transformation, the healthcare industry's changes are particularly striking. The advent of the big model era has swept from general domains to vertical ones. The application of big models in medicine has profoundly transformed the entire healthcare sector, potentially reshaping the medical ecosystem. As key participants in this process, Huawei and DHC have accumulated rich experience and technical strengths in their respective fields.
Huawei is a global leader in ICT infrastructure and smart devices, focusing on core advantages and root technologies in healthcare ICT top-level design. It proposes a shared "Health Intelligent Reference Architecture" for the health sector, releasing the "Smart Healthy City Technology Framework and Application Research Results Report." In terms of innovation in digital intelligence foundation, it continuously makes breakthroughs in root technologies and architectural innovation, co-building industries such as Kunpeng and Ascend with application manufacturers. In data elements and AI innovation, Huawei actively explores successful pilot experiences and technologies, addressing bottlenecks in data accessibility, flow, and usage through scenario demand traction. For over a decade, Huawei has contributed ICT technological force to digital transformation and intelligent upgrades in health, serving over 60% of medical institutions nationwide.
DHC is a leading company in the fields of medical big data and artificial intelligence, offering advanced products and excellent solutions for the entire health ecosystem. With over 1800 cooperative hospital clients and managing data governance experiences for over 300 million patient visits, DHC has successfully declared and completed several national key R&D programs during the "13th Five-Year Plan," "14th Five-Year Plan," "Science and Technology Innovation 2030," "863 Program," and other major national projects. Relying on AI technology and high-quality multimodal big data, DHC independently develops text, imaging, pathology, precision—four major modality foundation models supporting the medical field's multimodal big model. This creates a multimodal intelligent entity specific to the medical vertical domain, enabling deep governance of clinical, imaging, pathology, and genetic data to empower multiple scenario applications such as medical big data, clinical diagnosis and treatment, intelligent scientific research, and health management. It has been applied in prestigious hospitals like the Chinese PLA General Hospital, Southern Medical University Nanfang Hospital, Chongqing University Cancer Hospital, and the First Affiliated Hospital of Guangxi Medical University.
This cooperation marks the official commencement of deep collaboration between DHC and Huawei in the medical science and technology field. With continuous deepening of the partnership, it is believed that in the near future, both parties will work together to promote industry-academia-research collaboration in the medical field, establish a synergistic development ecosystem, create more medical scenario-based solutions, meet the digital needs of medical institutions at different development stages, accelerate the digital transformation of the healthcare industry, and jointly contribute to the high-quality development of health services and the implementation of the "Healthy China" strategy.
TOP
